Edition:
United States

Invacare Corp (IVC.N)

IVC.N on New York Stock Exchange

4.35USD
17 Dec 2018
Change (% chg)

-- (--)
Prev Close
$4.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
121,157
52-wk High
$19.95
52-wk Low
$4.12

Summary

Name Age Since Current Position

Matthew Monaghan

50 2015 Chairman of the Board, President, Chief Executive Officer

Kathleen Leneghan

54 2018 Chief Financial Officer, Senior Vice President

Anthony LaPlaca

59 2009 Senior Vice President, General Counsel, Secretary

Ralf Ledda

50 2016 Senior Vice President, General Manager - Europe, Middle East and Africa

C. Martin Harris

61 2015 Lead Independent Director

Susan Alexander

61 2016 Independent Director

Petra Danielsohn-Weil

58 2018 Independent Director

Diana Ferguson

55 2018 Independent Director

Marc Gibeley

53 2015 Independent Director

Clifford Nastas

55 2015 Independent Director

Baiju Shah

46 2011 Independent Director

Lois Lee

2017 Director, Treasury and Investor Relations

Biographies

Name Description

Matthew Monaghan

Mr. Matthew E. Monaghan is the Chairman of the Board, President, Chief Executive Officer of Invacare Corp. Prior to joining Invacare, Mr. Monaghan served as a business unit leader at Zimmer Holdings (now Zimmer Biomet NYSE: ZBH), a major orthopedic implant company, serving first as Vice President and General Manager of the company’s Global Hips business (December 2009 to January 2014) and later as Senior Vice President of Hips and Reconstructive Research (January 2014 until joining Invacare). While at Zimmer, Mr. Monaghan was responsible for the Hip division’s new product development, engineering, marketing, clinical studies, quality, regulatory affairs and results of the shared sales and supply chain functions. Later, those responsibilities also included directing global research for various areas of material, process and product innovation. Prior to joining Zimmer in 2009, Mr. Monaghan spent eight years as an operating executive for two leading private equity firms, Texas Pacific Group (TPG) and Cerberus Capital Management, where he led acquisitions and operational improvements of portfolio companies, which included the carve-out from Baxter Healthcare of a global medical business, making significant improvements at a U.S. personal insurance business and as COO of a consumer durable goods business spun off from Newell-Rubbermaid. For the first 13 years of his career, Mr. Monaghan held various engineering, financial and management positions at General Electric (NYSE:GE). Since November 2016, Mr. Monaghan has served as a director of INC Research (NASDAQ: INCR), a contract research organization serving the needs of pharmaceutical clients.

Kathleen Leneghan

Ms. Kathleen P. Leneghan is the Chief Financial Officer, Senior Vice President of Invacare Corp. Ms. Leneghan has been in the role of interim Chief Financial Officer of the company since November 26, 2017. Prior to her promotion, Ms. Leneghan was vice president and corporate controller since 2003. She has been with Invacare for 27 years, serving in various financial roles in both North America and Europe. Prior to joining Invacare, Ms. Leneghan was an audit manager with Ernst & Young LLP.

Anthony LaPlaca

Mr. Anthony C. LaPlaca is the Senior Vice President, General Counsel, Secretary of Invacare Corp. Mr. LaPlaca was appointed Senior Vice President, General Counsel and Secretary effective January 2009. Previously, Mr. LaPlaca served as Vice President and General Counsel for six and a half years with Bendix Commercial Vehicle Systems LLC, a member of the Knorr-Bremse group, a supplier of commercial vehicle safety systems. Prior to that, he served as Vice President and General Counsel to Honeywell Transportation & Power Systems and General Counsel to Honeywell Commercial Vehicle Systems LLC.

Ralf Ledda

Mr. Ralf Ledda is the Senior Vice President, General Manager - Europe, Middle East and Africa of Invacare Corp. Mr. Ledda has over 20 years of proven leadership experience at Alber GmbH, Invacare's German-based subsidiary that specializes in innovative electromotive technology and power add-on devices used with medical and recreational products. Most recently, he was the managing director of Alber. Mr. Ledda joined Alber in 1995. Mr. Ledda assumed responsibility for the company when it transitioned from its founding family ownership to Invacare. During his tenure, he has been responsible for all aspects of the company's operations including overseeing the launch of many innovative devices, including the current Alber Scalamobil stairclimbing systems, multiple power assist devices for manual wheelchairs, and Neodrive technology for e-bicycles. As part of Invacare's ongoing transformation to focus on clinically complex and post-acute care, the company continues to expand the availability of Alber products. Mr. Ledda has a degree in industrial engineering from the University of Munich. Prior to joining Alber, Mr. Ledda worked at Siemens AG.

C. Martin Harris

Dr. C. Martin Harris, M.D. is the Lead Independent Director of Invacare Corp. Dr. Harris also served as Invacare's Interim Chairman of the Board from December 2014 until May 2015. Since December 2016, Dr. Harris has served as the Associate Vice President of the Health Enterprise and Chief Business Officer of the Dell Medical School at The University of Texas, Austin. From 1996 until October 2016, Dr. Harris served as the Chief Information Officer and Chairman of the Information Technology Division of The Cleveland Clinic Foundation in Cleveland, Ohio and a Staff Physician for The Cleveland Clinic Hospital and The Cleveland Clinic Foundation Department of General Internal Medicine. Dr. Harris served from 2000 to 2016 as the Executive Director of e-Cleveland Clinic, a series of e-health clinical programs offered over the internet. Dr. Harris serves as a Director and member of the Audit Committee of HealthStream Inc. (NASDAQ: HSTM), Nashville, Tennessee, which provides internet-based learning and research solutions for the training, information, and education needs of the healthcare industry in the United States. He also serves on the Boards of Directors of Thermo Fisher Scientific Inc. (NYSE: TMO), Waltham, Massachusetts, which provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics and of Colgate Palmolive Company (NYSE: CL), New York, NY., a consumer products producer of household, dental and oral consumer products.

Susan Alexander

Ms. Susan H. Alexander, Esq. is an Independent Director of Invacare Corp. Ms. Alexander serves as the Executive Vice President, Chief Legal, Corporate Services and Secretary of Biogen Inc. (NASDAQ: BIIB), a biopharmaceutical company, since March 2017. Ms. Alexander has served as Executive Vice President, Chief Legal Officer and Corporate Secretary of Biogen from 2011 until March 2017 and as Executive Vice President, General Counsel and Corporate Secretary of Biogen from 2006 to 2011. Prior to joining Biogen, Ms. Alexander served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corporation (NASDAQ: PRXL), a biopharmaceutical services company from 2003 to 2006. From 2001 to 2003, Ms. Alexander served as General Counsel of IONA Technologies, a software company. From 1995 to 2001, Ms. Alexander served as Counsel at Cabot Corporation, a specialty chemicals and performance materials company. Prior to that, Ms. Alexander was a partner at the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne. The Board concluded that Ms. Alexander should serve as a Director of the Company primarily due to her experience in the bio- and med-tech industries gained through her legal leadership roles in Biogen and PAREXEL International. Ms. Alexander has a broad range of corporate legal experience both from private law and general counsel positions in global med-tech, software and manufacturing companies and will bring strong cross-functional legal, regulatory and senior management expertise to the Board. The Board believes that Ms. Alexander’s background and experience will be valuable in contributing to the Board’s oversight of the Company’s regulatory and compliance functions, particularly as the Company seeks to continue the transformation of its business and drive toward more clinically complex solutions in the health care industry.

Petra Danielsohn-Weil

Ms. Petra Danielsohn-Weil Ph.D., is an Independent Director of Invacare Corp. Ms. Danielsohn-Weil had served in various general management, regional and global business unit executive roles in Europe and the United States for Pfizer from 2000 until her retirement. Prior to that, she served in various commercial and strategic leadership roles in Europe and the US for Warner-Lambert from 1988 until its acquisition by Pfizer in 2000. She serves as a board member of NovaMedica LLP, a pharmaceutical company and a portfolio company of Rusnano JSC Corporation. Ms. Danielsohn-Weil holds an undergraduate degree in Educational Psychology, a Master's Degree in Chemistry and Biology and a PhD in Biology from the University of Munster in Germany.

Diana Ferguson

Ms. Diana Severs Ferguson is an Independent Director of Invacare Corp. Ms. Ferguson previously served as Chief Financial Officer of the Chicago Board of Education, from February 2010 to May 2011, and as Senior Vice President and Chief Financial Officer of The Folgers Coffee Company from April 2008 to November 2008. Prior to joining Folgers, she was Executive Vice President and Chief Financial Officer of Merisant Worldwide, Inc. Ms. Ferguson also served as the Chief Financial Officer of Sara Lee Foodservice and held several leadership positions at Sara Lee Corporation including Senior Vice President of Strategy and Corporate Development, as well as Treasurer. Ms. Ferguson currently serves as a director of Frontier Communications Corporation (NasdaqGS: FTR), a provider of communications services, and formerly served as a director of TreeHouse Foods, Inc. (NYSE: THS), a consumer-packaged food and beverage manufacturer. Ms. Ferguson holds a BA in Psychology from Yale University and an MBA from Northwestern University.

Marc Gibeley

Mr. Marc M. Gibeley is an Independent Director of Invacare Corp. Mr. Gibeley serves as Chief Executive Officer and Director of Scientific Intake Ltd. Co., a medical device and digital healthcare company focused on weight management and the prevention of obesity related chronic diseases, since October 2016. Prior to joining Scientific Intake, Mr. Gibeley served as Head of Diabetes Care North America for Roche Holding AG (SIX: RO), a leading research-focused pharmaceuticals and diagnostics healthcare company from 2011 through 2016. Mr. Gibeley served as the President and Chief Executive Officer of WaveRx, a venture-backed diabetes neuropathy medical device company, from 2008 through 2011. Prior to joining WaveRx, Mr. Gibeley worked for several consumer packaged goods companies, including Procter & Gamble (NYSE: PG), Eastman Kodak (NYSE: KODK) and Kraft Foods (NASDAQ: KHC). The Board concluded that Mr. Gibeley should serve as a Director of the Company primarily due to his extensive experience in leading and managing medical device companies that have undergone substantial changes and transformed to focus on marketing products directly to consumers. He has a wide range of management expertise, including in sales, marketing, finance, customer support and product launches, as well as in regulatory affairs, manufacturing, and operations and commercial development, which has been developed over a career in consumer products businesses at various stages of development. The Board believes that Mr. Gibeley’s background and experience will be valuable in contributing to the Board’s oversight of the Company’s strategy, finance and operations, particularly as the Company seeks to continue the transformation of its business and responds to the drive toward consumerism in the health care industry.

Clifford Nastas

Mr. Clifford D. Nastas is an Independent Director of Invacare Corp. Mr. Nastas has been the President and Chief Executive Officer of Radiac Abrasives Company, a manufacturer of conventional bonded and super abrasives in North America, since January 2016. Since 2014, Mr. Nastas has been a Director of Dan T. Moore Company, Inc., a holding company of diverse advanced materials manufacturing and technology businesses and became co-chairman in 2016. Also since 2014, Mr. Nastas has served as a Director of Shorr Packaging Corporation, an ESOP-owned company that distributes packaging supplies throughout North America. Mr. Nastas served as Chief Executive Officer and a Director of Material Sciences Corporation (formerly, Nasdaq: MASC), Elk Grove Village, Illinois, a publicly traded diversified industrial manufacturing company providing high-value coated metal, acoustical and lightweight composite solutions from 2005 until the company was sold in March 2014. From 2001 to 2005, Mr. Nastas served in various capacities at Material Sciences, including as President and Chief Operating Officer. Prior to joining Material Sciences, Mr. Nastas served in various general management, sales, and manufacturing capacities with Honeywell International, formerly Allied Signal (NYSE: HON), Morris Township, New Jersey, Avery Dennison Corporation (NYSE: AVY), Glendale, California, and Ford Motor Company (NYSE: F), Dearborn, Michigan. The Board concluded that Mr. Nastas should serve as a Director of the Company primarily due to his extensive business leadership and management expertise, which includes a broad range of experience in management, operations, sales, marketing, product development and engineering in a number of global businesses, including as the CEO of a publicly-traded company. The Board believes that Mr. Nastas’ experience and background will enable him to provide the Board will valuable insight into numerous aspects of the Company’s business.

Baiju Shah

Mr. Baiju R. Shah is an Independent Director of Invacare Corp. Mr. Shah has been the Chief Executive Officer and a Director of BioMotiv, LLC, a company focused on developing a portfolio of drug discoveries from research institutions into new medicines, since August 2012. Prior to that, Mr. Shah served as President and Chief Executive Officer and a Director of BioEnterprise Cleveland from 2004 to August 2012, Senior Vice President from 2003 to 2004 and a Vice President from 2002 to 2003. BioEnterprise is a Cleveland-based business formation, recruitment and acceleration initiative designed to grow health care companies and commercialize biomedical technologies. Prior to BioEnterprise, Mr. Shah worked for McKinsey & Company, where he was a leader in its Growth and Business Building practice. In addition, Mr. Shah serves as a member of the Citizens Financial Group (NYSE: CFG) advisory board. Mr. Shah also serves as a Director of multiple privately held biomedical-related companies in which BioMotiv, LLC has investments. The Board concluded that Mr. Shah should serve as a Director of the Company primarily due to his experience in the healthcare and biomedical industry gained through his leadership of BioMotiv and BioEnterprise. The business insight gained through his work at BioMotiv, BioEnterprise and McKinsey & Company, in particular, and his demonstrated abilities in advancing initiatives to help companies grow and expand, provides Mr. Shah with a perspective on healthcare business and growth initiatives that is invaluable to the Board.

Lois Lee

Basic Compensation

Name Fiscal Year Total

Matthew Monaghan

8,190,180

Kathleen Leneghan

532,626

Anthony LaPlaca

1,332,020

Ralf Ledda

1,313,310

C. Martin Harris

194,133

Susan Alexander

164,133

Petra Danielsohn-Weil

--

Diana Ferguson

--

Marc Gibeley

164,133

Clifford Nastas

174,133

Baiju Shah

179,133

Lois Lee

--
As Of  30 Dec 2017